BERLIN (Reuters) - Germany’s Carl Zeiss Meditec (AFXG.DE) on Wednesday lifted its full-year guidance, saying it has significantly outstripped its revenue forecast for the current fiscal year and reached an adjusted growth rate of 11.9%.
“From today’s point of view, the company expects a strong increase in operating earnings (EBIT) and anticipates to significantly exceed the previous forecast of an EBIT margin between 15.0% to 17.5%”, the company said.
Carl Zeiss Meditec is due to report full-year results on Dec. 6.
Shares were up 2.6% in Frankfurt at 0725 GMT.
Reporting by Tassilo Hummel, editing by Riham Alkousaa